Last reviewed · How we verify
Indomethacin Capsules high dose
Non-selective COX-1 and COX-2 inhibitor
Non-selective COX-1 and COX-2 inhibitor Used for Osteoarthritis, Rheumatoid arthritis.
At a glance
| Generic name | Indomethacin Capsules high dose |
|---|---|
| Sponsor | Iroko Pharmaceuticals, LLC |
| Drug class | NSAID |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 2 |
Mechanism of action
Indomethacin acts by inhibiting the enzyme cyclooxygenase (COX), which is responsible for the production of prostaglandins. This results in a decrease in the production of prostaglandins, which are mediators of inflammation and pain.
Approved indications
- Osteoarthritis
- Rheumatoid arthritis
Common side effects
- Gastrointestinal upset
- Renal impairment
- Hypersensitivity reactions
Key clinical trials
- Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity (PHASE3)
- Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study) (PHASE3)
- Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age (PHASE2)
- Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indomethacin Capsules high dose CI brief — competitive landscape report
- Indomethacin Capsules high dose updates RSS · CI watch RSS
- Iroko Pharmaceuticals, LLC portfolio CI